Madrigal Pharmaceuticals (NASDAQ:MDGL) Announces Quarterly Earnings Results

Madrigal Pharmaceuticals (NASDAQ:MDGL) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.99) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.68) by $0.69, FiscalAI reports. The company had revenue of $364.25 million for the quarter, compared to analysts’ expectations of $352.13 million. Madrigal Pharmaceuticals had a negative net margin of 27.32% and a negative return on equity of 50.15%. Madrigal Pharmaceuticals’s revenue was up 71.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.90) EPS.

Here are the key takeaways from Madrigal Pharmaceuticals’ conference call:

• Rezdiffra sales and patient growth remained strong: Second-quarter net sales reached $364.3 million, up 71% year over year, with more than 49,000 active patients at quarter-end and over 50,000 reached in July. Management said it remains comfortable with consensus growth expectations for the rest of 2026.
• The U.S. addressable F2/F3 MASH market has expanded nearly 50% since year-end 2023, while diagnosis and treatment penetration remain low. Madrigal expects double-digit market growth for the foreseeable future and views the untreated F4C population as potentially capable of doubling Rezdiffra’s opportunity.
• Madrigal reported progress in extending Rezdiffra’s commercial life and building its pipeline, including new patents supporting F2/F3 protection through 2045 and additional F4C protection into the 2040s. The company expects to initiate three Phase II combination trials in 2027 involving an oral GLP-1, a DGAT2 inhibitor, and an siRNA targeting PNPLA3.
• The F4C MAESTRO-NASH Outcomes trial continues to accrue events and remains on track for a 2027 readout, but executives did not provide a more precise timing estimate or confirm the final event threshold. Management emphasized that the trial is pioneering and that event-rate uncertainty makes timing difficult to narrow.
• Despite strong revenue growth, the company posted a second-quarter net loss of $57.9 million, while cash, restricted cash, and marketable securities declined to $838.9 million from $988.6 million at year-end 2025. SG&A is expected to rise in 2026 as Madrigal continues commercial investment, and European revenue is expected to remain negligible because of reimbursement and pricing uncertainty.

Madrigal Pharmaceuticals Price Performance

Madrigal Pharmaceuticals stock traded down $53.77 during midday trading on Thursday, reaching $493.11. The company’s stock had a trading volume of 1,487,641 shares, compared to its average volume of 269,116. The firm has a market capitalization of $11.37 billion, a PE ratio of -38.52 and a beta of -1.05. Madrigal Pharmaceuticals has a fifty-two week low of $290.00 and a fifty-two week high of $615.00. The stock’s 50 day simple moving average is $517.48 and its 200 day simple moving average is $499.27. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.16 and a current ratio of 3.50.

Trending Headlines about Madrigal Pharmaceuticals

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Revenue and EPS beat expectations. Madrigal reported second-quarter revenue of $364.25 million, up 71.2% year over year and above the $352.13 million consensus estimate. Its loss of $1.99 per share was also narrower than analysts’ expected $2.68 loss. Madrigal Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: Commercial performance remains a key strength. The substantial year-over-year revenue increase supports the continued launch and adoption of Madrigal’s MASH therapy, Rezdiffra, and provides evidence of growing demand for the company’s lead product. Madrigal Second-Quarter 2026 Results
• Positive Sentiment: Wells Fargo maintained a constructive view. Analysts at Wells Fargo assigned MDGL an Overweight rating, indicating expectations for further upside despite near-term volatility. Wells Fargo Overweight Rating
• Neutral Sentiment: Management’s earnings call and presentation provided additional corporate updates. Investors are focused on product execution, commercial expansion and the company’s progress toward improving operating results. Q2 2026 Earnings Call Transcript
• Negative Sentiment: Madrigal remains unprofitable. Although the quarterly loss beat estimates, the company continues to report negative net margin and return on equity, while analysts expect a full-year loss. That ongoing cash-burn and execution risk may be weighing on the shares, particularly after their strong prior performance. Madrigal Q2 2026 Earnings

Insiders Place Their Bets

In other news, insider David Soergel sold 1,042 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $495.74, for a total transaction of $516,561.08. Following the transaction, the insider directly owned 10,033 shares of the company’s stock, valued at $4,973,759.42. This represents a 9.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard S. Levy sold 5,682 shares of the stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $515.44, for a total transaction of $2,928,730.08. Following the completion of the transaction, the director owned 22,015 shares of the company’s stock, valued at $11,347,411.60. This represents a 20.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 7,568 shares of company stock worth $3,880,711. Corporate insiders own 17.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Quarry LP purchased a new stake in shares of Madrigal Pharmaceuticals during the 3rd quarter worth approximately $39,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Madrigal Pharmaceuticals in the 4th quarter worth approximately $39,000. Johnson Financial Group Inc. purchased a new position in Madrigal Pharmaceuticals in the 3rd quarter valued at approximately $50,000. Kestra Investment Management LLC purchased a new position in Madrigal Pharmaceuticals in the 2nd quarter valued at approximately $85,000. Finally, Smartleaf Asset Management LLC increased its stake in Madrigal Pharmaceuticals by 50.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 187 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 63 shares in the last quarter. 98.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

MDGL has been the topic of several analyst reports. Bank of America lowered their target price on shares of Madrigal Pharmaceuticals from $550.00 to $542.00 and set a “neutral” rating on the stock in a report on Thursday, June 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a report on Friday, July 17th. HC Wainwright restated a “buy” rating and issued a $620.00 price objective on shares of Madrigal Pharmaceuticals in a research report on Wednesday, May 6th. Truist Financial lifted their price objective on Madrigal Pharmaceuticals from $640.00 to $709.00 and gave the company a “buy” rating in a report on Wednesday, May 13th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Madrigal Pharmaceuticals in a report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $688.33.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.